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Abstract
Post-marketing surveillance of medical pharmaceuticals and devices has received a great
deal of media, legislative, and academic attention in the last decade. Among medical devices,
these have largely been due to a small number of highly publicized adverse events, some of them
in the domain of cardiac surgery and interventional cardiology. Phase three clinical trials for
these devices are generally underpowered to detect rare adverse event rates, are performed in
near-optimal environments, and regulators face significant pressure to deliver important medical
devices to the public in a timely fashion.
All of these factors emphasize the importance of systematic monitoring of these devices
after being released to the public, and the FDA and other regulatory agencies continue to struggle
to performthis duty using a variety of voluntary and mandatory adverse event rate reporting
policies. Data quality and comprehensiveness have generally suffered in this environment, and
delayed awareness of potential problems. However, a number of mandatory reporting policies
combined with improved standardization of data collection and definitions in the field of
interventional cardiology and other clinical domains have provided recent opportunities for
nearly "real-time" safety monitoring of medical device data.
Existing safety monitoring methodologies are non-medical in nature, and not well
adapted to the relatively heterogeneous and noisy data common in medical applications. A web-
based database-driven computer application was designed, and a number of experimental
statistical methodologies were adapted from non-medical monitoring techniques as a proof of
concept for the utility of an automated safety monitoring application. This application was
successfully evaluated by comparing a local institution's drug-eluting stent in-hospital mortality
rates to University of Michigan's bare-metal stent event rates. Sensitivity analyses of the
experimental methodologies were performed, and a number of notable performance parameters
were discovered. In addition, an evaluation of a number of well-validated external logistic
regression models, and found that while population level estimation was well-preserved,
individual estimation was compromised by application to external data. Subsequently,
exploration of an alternative modeling technique, support vector machines, was performed in an
effort to find a method with superior calibration performance for use in the safety monitoring
application.
Thesis Supervisor: Frederic S. Resnic
Title: Assistant Professor of Medicine, Harvard Medical School
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Introduction
Post-marketing surveillance of medical devices by the Food and Drug Administration
(FDA) has undergone tremendous change in the last few decades. 1-4 These changes were largely
due to a small number of highly publicized adverse events; some of them in the domain of
cardiac surgery and interventional cardiology. 3' 5-13
Medical devices are frequently released quickly because of the need to deliver potentially
lifesaving medical advances to the public. Rare adverse events are an ongoing concern in this
environment because they may not be discovered in pre-marketing trials due to a small sample
sizes and a bias towards healthier subjects.14 To balance this, the FDA has shifted more of its
device evaluation to the post-marketing period.1 5 This creates the potential for large numbers of
patients to be exposed to a new product in the absence of long-term follow-up data, and
emphasizes the need for comprehensive methods in post-marketing surveillance.1 6
The data the FDA uses to conduct this surveillance is very heterogeneous, and results
from a variety of voluntary and mandatory reporting policies.1 6 14, 7-22 The voluntary policies
create significant limitations in event rate recognition through underreporting, bias, and highly
variable reporting quality.' 4 In response, some agencies have implemented mandatory reporting
for medical devices in certain clinical areas, and medical societies have made strides in
standardizing data element definitions within their respective domains.23
Continued improvements in the quality and volume of reported data have created
opportunities for timely and efficient analysis and reporting of alarming trends in patient
outcomes. However, standard techniques regarding alerting thresholds and benchmarking
methodologies do not exist for post-marketing medical device surveillance. Non-medical
industries have been using a variety of automated statistical process control (SPC) techniques for
some time for comparable quality control purposes. 28-32 These systems rely on high-quality
automated data collection, and apply stringent error thresholds24 that make direct application of
these methods for medical devices difficult.
Statistical process control is a classical frequentist technique typically comparing
observed event rates to acceptable rates of adverse events based on previously published or
observed empirical data. However, this is very limiting when no or very limited prior empirical
data are available. Another methodology, Bayesian updating statistics (BUS), seeks to address
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this limitation directly through the construction and explicit use of prior probability estimates
and provide direct comparison of the final posterior distribution to the prior estimate.
Establishing a standard methodology for the selection and incorporation of prior
empirical data to generate alerting thresholds integral is integral to this endeavor. Both SPC and
BUS provide for population-level thresholds with static risk stratification. Logistic regression
(LR) is the most popular of the modeling techniques that have been developed over the last few
decades to help stratify and predict risk for patient subpopulations. These models have been
widely used to improve the quality of care,2 5 provide institutional quality scorecards2 6, provide
risk stratification2 7 and assist patient selection28 in research, evaluate futility of care,29 and to
provide individual patient prognostications. The ability of LR to individually risk stratify a
patient using a large number of clinical factors could be used to develop a stand-alone
monitoring methodology, or be used synergistically with other methods as a risk stratification
tool.
Interventional cardiology (IC) is an ideal medical domain to pioneer prospective real-
time safety monitoring in medical devices for a number of reasons. Not only has IC been an
active area of medical device development in recent years, but it is one of the few domains with
high quality comprehensive data. This is largely due to the development of a national
standardized data dictionary,23 and an increase in mandatory electronic data collection and
reporting by some state agencies.
In addition, there are a number of well-known LR mortality risk models that have been
developed in IC over the last 15 years.30 35 Several studies of these models have shown good
36-40
external validation with respect to both calibration and discrimination.3 6 4 Others have shown a
loss in either discrimination, calibration, 4 or both.42 This is thought to be primarily related to
medical practice and patient composition changes related to geography and time.43 ' 44 A study
comparing the demographics of percutaneous coronary intervention (PCI) patients in two
registries collected twelve years apart found significant differences in a number of important risk
factors. 45
This highlights the need for a thorough evaluation of existing and newly developed LR
models for use with a safety monitoring system. Also, exploration of alternative modeling
techniques, such as a new machine learning technique called Support Vector Machines (SVM),
could potentially improve risk stratification performance in this domain.
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The specific goals of this project are to:
1) Develop local logistic regression (LR) risk models, and validate both local and well-
known external LR models in order to optimize this modeling method for use in a
real-time safety monitoring tool.
2) Explore a recent advance in machine learning, support vector machines, as an
alternative risk modeling and stratification method for use in the monitoring
application.
3) Develop prospective methods of statistical monitoring and alerting thresholds.
Exploration of these methods will include derivations of statistical process control,
Bayesian updating statistics, and logistic regression based risk stratification and
assessment.
4) Implement a web-based safety monitoring tool in interventional cardiology that
allows detailed evaluation of specific outcomes.
5) Perform a sensitivity analysis between statistical process control and Bayesian
statistical updating monitoring methods on interventional cardiology data.
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Manuscript Organization
This manuscript will be organized into four chapters. Chapter One will describe the
design of a new local logistic regression model for the outcome of post-intervention in-hospital
death. This model will then be internally validated, and external validation will be conducted on
a number of well-known logistic regression models for this outcome from other centers.
Chapter Two which will explore a new machine learning methodology, support vector
machines, to determine if the use of this risk modeling method would be a reasonable addition to
the safety monitoring tool.
The results of the LR model evaluations were incorporated into the design and
development of the statistical methodologies necessary to conduct real-time safety monitoring.
The development of these methods, as well as the implementation of a web-based application
providing this type of analysis, will be described in Chapter Three.
A sensitivity analysis between statistical process control and Bayesian updating statistics
methodologies will be performed in Chapter Four. Actual interventional cardiology data will be
used to provide scaled outcome rates for evaluation over a range of baseline event rates and
volumes. A conclusion will then summarize the findings in each portion of the work.
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Chapter 1: Performance Evaluation of Logistic Regression Risk Model
Background
In the last decade, significant emphasis has been placed on the development of statistical
models to help predict risk in various patient populations. In addition to providing the basis for
quality scorecards, 26 46 these risk profiles can be helpful on the procedural level to both patients
and physicians. Numerous studies have shown that subjective prediction of risk tends to be poor
at very low and very high probabilities. 47' 48 The use of various statistical methods can provide
an objective estimation of outcome risk.
There has been conflicting literature on whether or not these models can be used outside
of their development population. Initial validation is usually based on patients from a given
geography and time frame. These evaluations are only directly applicable in that respect, and
concerns have been raised about the applicability of a model when patient demographics change
with geography, clinical practice changes with time, and disease prevalence changes with both.
Some of this concern stems from prior analyses showing deleterious effects on accuracy by
changes in geography and time.4 3 A study comparing the demographics of percutaneous
coronary intervention (PCI) patients in two registries collected twelve years apart found
significant differences in age, lesion severity, thrombolytic use, stent use, and death that
highlight how much the characteristics of a population can change with a decade of medical
advances. 45
Continuous evaluation of model performance is important to ascertain that classification
performance does not degrade with time. Some models are re-developed periodically to adjust
for temporal trends.49 Also important is validation of a model on geographically or temporally
distant populations.50 Constructing a model using a large numbers of patient encounters across a
wide variety of geographic areas increases the probability that the model will be suited for
different populations, but the only way to determine the model's applicability is to verify the
performance empirically in representative sample.
In the field of cardiology, one of the most widely studied areas of risk stratification has
been coronary angiography. This article seeks to build on prior work on the applicability of risk
models in different geographies and over time. Several prior studies of PCI risk models have
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shown good external validation with respect to both calibration and discrimination.36-40 Others
41 4have shown a loss in either discrimination, calibration, 4 or both.42 In the present study we
consider the hypothesis that models exhibit differences in discrimination and calibration over
space and time.
Methods
Data Collection
Brigham & Women's Hospital (BWH), Boston Massachusetts has maintained a detailed
database of all cases of PCI since 1997. The dataset is based on the American College of
Cardiology National Data Repository dataset,23 with a variety of additional, detailed, data
elements. The registry is part of the quality assessment and quality improvement program of
Brigham & Women's Hospital, and was approved by the hospital Institutional Review Board.
All catheterization laboratory procedures performed are included in the database, and real-time
data acquisition is accomplished through a dedicated team of trained nurses, physicians and
technologists. A total of 5,216 PCI procedures were recorded between January 01, 2002 and
September 30, 2004 on all patients who underwent PCI at BWH. This data set serves as the
source for the evaluation of each model in this study.
Model Evaluation
Evaluation of all models was done with 2 and maximum log likelihood methods.
Discrimination was assessed with the area under the receiver operating characteristic curve
(AUC).51 ' 52 A summary of each of the models used is shown in Table 1. Calibration was
evaluated with Hosmer-Lemeshow goodness-of-fit x2- estimates using deciles.53 95%
confidence intervals for these parameters were computed with the non-parametric bootstrapping
method of STATA (Version 8.2, College Station, TX).54 These CIs were reported using the
percentile method, or bias corrected method if the estimation bias was greater than 25% of the
standard error.5 5
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Model Dates Location Sample AUC HL(p) Validation Type
NNE 1999 1/1/1994 12/31/1996 NH, ME, MA, VT (7) 15331 0.88 0.09 Bootstrap Resampling
NY 1992 1/1/1991 6/30/1991 NY 5827 0.884 NA Subset Significance
NY 1997 1/1/1991 12/31/1994 NY 62670 0.892 0.11 Subset Significance
Ml 2001 10/1/1999 8/30/2000 Detroit, Ml 10796 0.90 0.5 Training/Test
ACC 2002 1/1/1998 9/30/2000 National 100253 0.89 0.133 Training/Test
BWH 2001 1/1/1997 12/31/1999 Boston, MA 2804 0.86 0.11 Training/Test
CC 1997 1/11993 12/31/1994 Cleveland, OH (5) 12985 0.846 NA Bootstrap Resampling
Table 1: Summary of the training data sets for the models used in this study. Sample = sample size. AUC = area
under the receiver operating characteristic. HL(p) = Hosmer-Lemeshow p value.
External Validation of Risk Models
Six external and one local previously described multivariate post-PCI in-hospital
mortality risk models were evaluated using the BWH data set: the Northern New England
Cooperative Group (NNE 1999),3° the New York State (NY 1992 & NY 1997),31 32 University
of Michigan Consortium (MI 2001),33 the American College of Cardiology-National
Cardiovascular Data Registry (ACC 2002),34 the Cleveland Clinic Foundation Multi-Center (CC
1997),35 and the Brigham & Women's Hospital (BWH 2001)56 models. Pair-wise comparison of
the area under the ROC curve for each model was performed by Analyse-It (Version 1.71, Leeds,
England, UK).
Local Model Development
To test the hypothesis that time and space degrade the accuracy of a risk model, a new
local model was developed using the same BWH data that was used to evaluate the
discrimination and calibration of existing models. Standard univariate methods were used to
generate odds ratios (ORs) with 95% confidence intervals (CIs) and p values to select variables
that would be included in the new model.5 7 Additionally, all available covariates which have
been shown to be univariate risk factors in previous studies were included in the analysis (Table
2). Backward stepwise logistic regression was performed using STATA.19 Variables were first
removed using a residual Wald chi-square p value of 0.1, and then considered for inclusion based
on a p value of 0.05. Since there was no independent test set, the evaluation was based on
bootstrap resampling with 1000 samples.5 8
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Factor % Pts % Deaths OR 95% CI p
Age
<50
50-59
60-69
70-79
>79
Gender
Male
Female
Diabetes
PVD
COPD
Shock
Unstable Angina
Urgency
Elective
Urgent
Emergent
Salvage
LVEF
>39
20-39
<20
Tachycardia
Pre-PCI IABP
AMI 24 Hr
Cr > 2.0 mg/dL
CHF
Prior PCI
Prior CABG
Lesion Risk
Low
High
Intervention
LAD
Disease Location
Proximal LAD
RCA
Diseased Vessels
0
1
2
3
11.0
21.6
27.8
27.6
11.9
70.7
29.3
31.7
9.5
10.6
1.7
4.9
49.9
37.9
11.8
0.4
91.3
7.6
1.1
2.4
0.7
10.6
5.3
10.1
33.8
1101
66.3
33.7
42.4
47.2
52.3
9.0
52.6
25.5
12.8
0.2 1.00
0.4 2.55
0.9 5.20
1.5 8.91
4.8 29.3
1.4
1.4
1.8
2.4
2.0
37.4
11.6
0.3
0.9
5.7
45.4
1.1
3.6
5.5
13.5
19.4
5.2
5.0
4.0
0.5
1.1
0.5
3.0
1.9
2.2
1.7
0.4
0.9
1.9
3.0
1.00
1.02
1.58
1.97
1.55
82.0
15.8
1.00
2.98
19.6
270.3
1.00
3.22
5.04
14.5
19.3
6.1
4.5
3.9
0.28
0.76
1.00
5.5
1.87
3.34
1.69
1.00
2.07
4.5
7.3
Table 2: Univariate Association of Factors with In-Hospital Mortality and Registry Demographics. % Pts = percent
of sample population. % Deaths = percent of deaths within the sub-population. OR = Odds Ratio. 95% CI = 95%
Confidence Interval. p = p Value. PVD = Peripheral Vascular Disease. COPD = Chronic Obstructive Pulmonary
Disease. LVEF = Left Ventricular Ejection Fraction. PCI = Percutaneous Coronary Intervention. IABP = Intra-
Aortic Balloon Pump. AMI = Acute Myocardial Infarction. Cr = Creatinine. CHF = Congestive Heart Failure.
CABG = Coronary Artery Bypass Grafting. LAD = Left Anterior Descending. RCA = Right Coronary Artery.
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Ref
0.30 - 39.9
0.68 - 39.9
1.199 - 66.3
3.98 - 215.5
Ref.
0.61 - 1.70
0.99 - 2.5
1.05 - 3.69
0.81 - 2.97
48.1 - 139.8
9.7 - 25.7
Ref
1.3 - 6.9
9.1 -42.6
91 - 803.2
Ref
1.77 - 5.84
1.53- 16.6
8-17 - 25.9
8.15 -45.7
3.8 - 9.8
2.5 - 8.3
2.3 - 6.5
0.14 - 0.57
0.41 - 1.42
Ref
3.24 - 9.4
1.17 - 3.01
1.95 - 5.72
1.03 - 2.76
Ref.
0.49 - 8.8
1.06- 19.1
1.7 - 31.2
0.392
0.112
0.033
0.001
0.952
0.058
0.034
0.183
<0.001
<0.001
0.010
<0.001
<0.001
<0.001
0.008
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.385
<0.001
0.010
<0.001
0.036
0.323
0.041
0.008
Results
Local Multivariate Prediction Rule Development
After full backward stepwise variable selection, the variables associated with an
increased risk included older age, diabetes, unstable angina, salvage procedure, cardiogenic
shock, AMI, and any intervention on the left anterior descending artery as shown in Table 3.
The AUC was 0.929 revealing excellent discriminatory ability of the new model, and bootstrap
re-sampling the data to obtain a 95% CI of 0.90-0.96 with an SE of 0.017, indicating a good
ability to discriminate with respect to the outcome of death. The model had an adequate
2goodness of fit (HL X=7.61 with 8 d.f., p=0.473).
Factor OR 95% CI p
Prior PCI 0.30 0.12 - 0.74 -1.20 0.009
Age (yrs)
60-69 4.41 1.31 - 14.84 1.48 0.016
70-79 8.25 2.58 - 26.34 2.11 <0.001
80+ 21.39 6.76 - 66.97 3.06 <0.001
Diabetes 1.82 1.02- 3.26 0.60 0.042
Unstable 5.46 2.82 - 10.52 1.70 <0.001
Salvage 19.25 5.06 - 73.24 2.96 <0.001
Shock 14.86 7.39 - 29.87 2.70 <0.001
AMI Present 1.72 1.37 - 2.17 0.54 <0.001
Any LAD PCI 1.72 0.97 - 3.07 0.54 0.066
Table 3: Multivariate Analysis of Factors Significantly Associated with In-Hospital Mortality in the New BWH
model. OR = Odds Ratio. 95% CI = 95% Confidence Interval. 13 = Beta Coefficient. p = p Value. Constant
(intercept) = -7.777; Hosmer and Lemeshow goodness-of-fit X2 = 7.61; p = 0.473; AUC = 0.929. AMI = acute
myocardial infarction. LAD = left anterior descending. PCI = percutaneous coronary intervention.
External Validation
The external model performances on the BWH dataset are shown in Table 4. During the
study period there were 71 observed deaths (1.36%). BWH 2004 very closely approximated this
with 70.5 deaths, NY 1992, CC 1997, and BWH 2001 over predicted, and the remainder under
predicted. The AUC indicates excellent discrimination across all models, with the worst being
the New York State 1992 model and the best being the new local model. A summary view of the
AUC for all models is shown in Figure 1. Of the external models, the best AUC was obtained by
the ACC 2002 model.
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Curve Deaths AUC 95% CI HL X2 95% CI HL (p) 95% CI
NY 1992 96.7 0.82 0.76 - 0.88 31.1 13.9 - 50.0 <0.001 <0.001 - 0.003
NY 1997 61.6 0.88 0.81 - 0.92 32.2 16.4 - 45.5 <0.001 <0.001 - 0.004
CC 1997 78.8 0.88 0.82 - 0.93 27.8 19.6 - 38.7 <0.001 <0.001 - 0.013
NNE 1999 56.2 0.89 0.84 - 0.94 45.9 31.9 - 67.4 <0.001 <0.001 - <0.001
MI 2001 61.8 0.86 0.81 -0.90 30.4 16.7 - 43.1 <0.001 <0.001 - 0.011
BWH 2001 136.1 0.89 0.84 - 0.93 39.7 23.2 - 73.3 <0.001 <0.001 - 0.001
ACC 2002 49.9 0.90 0.84 - 0.95 42.0 24.9 - 63.3 <0.001 <0.001 - 0.002
BWH 2004 70.5 0.93 0.89 - 0.96 7.61 1.5 - 14.2 0.473 0.073 - 0.992
Table 4: Summary of discrimination and calibration performance for each model. Deaths = Estimated Deaths. AUC
= Area Under the Receiver Operating Characteristic Curve. 95% CI = 95% Confidence Interval. HL x2 = Hosmer-
Lemeshow X2. HL(p) = Hosmer-Lemeshow probability > x2 Value.
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Figure 1: AUC for all models. The grey line shows no discrimination.
Pair-wise AUC comparisons were performed as well, shown in Table 5, by using the
method described by Hanley and McNeil.5 9 Overall, the best discrimination was obtained by the
new local model, which attained significance with respect to every model but ACC 2002. The
second best performance was by the external model constructed with the largest training set
(ACC 2002), followed by the old local model (BWH 2001). Significant differences were noted
between NY 1992 and every model but MI 2001, as well as between MI 2001 and ACC 2002.
This indicates that the NY 1992 model, and to a lesser extent the MI 2001 model, is the least
discriminatory.
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No discrimination
BWH 2004
ACC 2002
NNE 1999
BWH 2001
-NY 1992
.... NY 1997
- M 2001
CC 1997
NY 1992 NY 1997 CC 1997 NNE 1999 MI 2001 BWH 2001 ACC 2002
Diff p Diff p Diff p Diff p Diff p Diff p Diff p
NY 1992
NY 1997 0.056 0.007
CC 1997 0.051 0.101 0.004 0.859
NNE 1999 0.062 0.013 -0.007 0.712 0.011 0.644
MI 2001 0.041 0.165 -0.015 0.485 -0.01 0.627 -0.022 0.310
BWH 2001 0.066 0.019 0.011 0.602 0.015 0.551 0.004 0.849 0.026 0.287
ACC 2002 0.080 0.002 0.025 0.145 0.03 0.176 0.018 0.254 0.040 0.045 0.014 0.519
BWH 2004 0.105 0.001 0.049 0.007 0.053 0.011 0.043 0.048 0.064 0.003 0.038 0.050 0.024 0.176
Table 5: Pair-wise Discrimination Model Comparison. Diff = AUC difference. p = p value of difference.
The Hosmer-Lemeshow goodness-of-fit test reveals poor calibration (p < 0.05) for all the
models but the newly developed one. Calibration for all models was further explored by plotting
the observed to expected frequency of death for each quintile of every model. Figure 2-B is
provided to more clearly show the relationships for the low risk population. As shown in Figure
2. the NY 1992 model underestimated the risk of death for low scoring patients, and over
estimated this risk for high scoring patients. NY 1997 performed fairly well for low risk
patients, but overestimated the probability of death for high risk patients. ACC 2002 performed
well under low risk conditions, but significantly underestimated the probability of death for high
risk conditions. NNE 1999 consistently under predicted deaths, and CC 1997 as well as BWH
2001 consistently overestimated mortality risk. As expected, BWH 2004 performs well, but
since this is not an independent test sample, this result should be interpreted with caution.
15
0.07
Figure 2-A: The observed and expected mortality rates for each quintile of patient risk. Each risk quintile contains
approximately 1050 patients. The diagonal line represents a perfect agreement between observed and expected
mortality estimates.
Figure 2-B: Expanded View from 0 to 0.15 of the Observed to Expected Probability Ratios.
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Discussion
Interventional cardiology practice has changed significantly over the last decade.
Procedural skill development, pharmacology, and device development have all contributed to the
evolution of the field, and patient outcomes have changed over that time period in response to
these advances. There as been a substantial reduction in risk of death and major adverse cardiac
events (MACE)60 over the past decade. All of these factors create a moving target for any risk
stratification model.
All the external models evaluated on the BWH data set showed good discrimination. The
model with the worst discrimination was NY 1992, which was to be expected due to the age of
the study, and small sample size with which the model was developed. The best external model
was the one developed on a national database with the most patient records, suggesting that
geographic issues may be related to discrimination. Although these results are promising, it is
important to note that discrimination is not the only (and possibly not the most important) factor
in determining the applicability of a prognostic model from the perspective of physicians and
patients. A model can exhibit perfect discrimination but still be useless for application on
individual cases. Good calibration is essential for this type of application. All models, except
possibly the one developed locally with recent data, but including a model derived locally,
showed poor calibration for our test set, suggesting that time may play an important role in the
applicability of a model.
Similar findings have been previously reported. Some techniques have been suggested to
recalibrate the model.6 1 One of these techniques was employed by Kizer, et al41 and Peterson, et
,162
al62 with some success, and may offer a strategy to maintain discrimination and improve
calibration.
This study supports routine evaluation of any risk model, including aging local models,
prior to local implementation. Discrimination was maintained for most risk adjustment models,
though those more recently published and those based on the largest original datasets appeared to
have the most robust discrimination when applied to a current clinical dataset. The preservation
of discrimination supports the use of these models for generic risk stratification, but the poor
17
calibration indicates that they are not useful for application in individual cases: the estimated risk
of death for a single patient that is produced by these models is incorrect.
The poor calibration of the prior models suggests that variations in practice and patient
demographics as well as clinical features over time have a large effect at the patient level on the
risk estimate's accuracy. Further study is required to identify the optimum frequency of model
recalibration.
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Chapter 2: Performance Evaluation of Support Vector Machine Risk Models
Background
In the last few decades, significant emphasis has been placed on the development of
statistical models to help predict risk in various patient populations. These models have been
'25 S26
widely used to improve the quality of care,2 provide institutional quality scorecards26 , provide
risk stratification 27 and assist patient selection 28 in research, evaluate futility of care,29 and to
provide individual patient prognostications.
Percutaneous coronary intervention (PCI) is one of the most common procedures in
cardiology, and is associated with significant morbidity and mortality. Opportunities for
providing objective risk assessment in this domain have been improving since the development
23
of a national standardized data dictionary, 23 and an increase in mandatory electronic data
collection and reporting by some state agencies.
The gold standard modeling technique in this domain is logistic regression (LR). There
are a number of well-known LR mortality risk models that have been developed over the last 15
years.30-35 Discrimination of these models is generally high, and has been retained in external
validation studies. However, calibration degraded when these models were applied to
subsequent local or external data.74 There are a number of possible explanations for this,
including changing medical practice, differing patient demographics, and different access to
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resources.
Calibration failure primarily affects individual patient prognostication, and negatively
impacts risk stratification and any application that relies on individual estimates. Recalibration
techniques are being explored to provide adequate calibration over time, but no method has
emerged as a standard.
Application of a modeling technique that outperforms LR in terms of calibration can
extend the useful life of a risk model before recalibration or model refitting is required. One of
the most recent developments in artificial intelligence modeling has been Support Vector
Machines (SVM). These models are able to find an optimal separation hyperplane in a multi-
dimensional space to perform classification of a dichotomous outcome. To our knowledge, this
methodology has not been explored in interventional cardiology, and has potential applications
in a number of applications, such as real-time safety monitoring of new medical devices.75
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In this study, we seek to evaluate and compare the discrimination and calibration
performance between a variety of LR and SVM risk models in the evaluation of post-procedural
in-hospital mortal ity in PCI.
Methods
Source Data
Data were collected from Brigham and Women's Hospital (BWH) (Boston, MA)
containing all cases (7914) of percutaneous coronary interutaneous interve tion (PCI) performed at the
institution from January 1, 2002 to December 31, 2005. The outcome of interest was post-
procedural in-hospital death, and there were 124 (1.57%) events during the collection period.
The cases were used to generate 100 random data sets. All cases were used in each set, and 5540
were allocated for training and 2374 were allocated for testing. For SVM evaluation, each
training set was randomly divided into 3957 kernel training and 1583 sigmoid training portions.
Data element definitions were based on the American College of Cardiology - National
Cardiovascular Data Registry (ACC-NCDR) data dictionary.2 3 The BWH Institutional Review
Board approved this study.
Acute Heart Attack Hx COPD
Age Hx PVD
Body Mass Index Hx Stroke
CHF Class Hyperlipidemia
CHF on Presentation Hypertension
Creatinine > 2.0 mg/dL IABP
Diabetes Prior PCI
Elective Case Shock
Emergent Case Unstable Angina
Family Hx Heart Disease Urgent Case
Heart Rate
Table 1: Hx = history, COPD = Chronic Obstructive Pulmonary Disease, PVD = Peripheral Vascular Disease, CHF
= Congestive Heart Failure, PCI = Percutaneous Coronary Intervention, IABP = Intra-Aortic Balloon Pump.
Variable Selection
After careful literature review, all previously identified risk factors for PCI were selected
for inclusion in this study.3 03 5' 56 Univariate analysis was then performed with SAS 9.1 (Cary,
NC). Variables not significantly associated with the outcome of death were removed from the
data (sex, smoking status, prior myocardial infarction, prior CABG, and a history of chronic
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renal insufficiency). A total of 21 variables were retained for use in model creation and analysis.
These variables are listed in Table 1.
Logistic Regression
Model development for LR was performed using the PROC LOGISTIC of SAS. A
standard backwards stepwise model selection method was used.80 In addition, 3-fold cross-
validation (CV) was performed on each training set to determine the optimum threshold for
feature selection in the backwards stepwise method. The modeling parameters were optimized
separately for mean squared error (MSE), Area under the Receiver Operating Characteristic
(AUC) curve, and Hosmer-Lemeshow (HL) %2 goodness-of-fit values. The thresholds evaluated
were 0.05 to 0.50, in 0.05 increments. The optimized threshold parameters were then used to
generate a model for each entire training data set, and then applied to the respective test data.
Support Vector Machine
The Support Vector Machine (SVM) models were developed using GIST 2.2.1
(Columbia University, New York, NY). Radial (SVM-R) and polynomial (SVM-P) based
kernels were selected for evaluation because of their good performance in other domains.
Polynomial kernels transform the feature matrix using the following equation, where X and Y
are features (predictors) and the class variable, respectively:
K(X, Y) = (X o + 1)
The primary kernel parameter is the power, represented as d in the above equation. Gaussian
radial-based kernels81 transform the feature matrix using the following equation:
-IIx-yll2
K(X,Y) = e 2w2
The primary kernel parameter is the width function, represented as w in the above equation. The
other parameter that can be used in both kernels is the cost function, which determines the ratio
of error weight between false positives and false negatives. This parameter was fixed constant at
a value of 1. Classification SVMs give outputs as a binary classifier (-1, 1) and also as a
continuous discriminant (distance from the hyperplane). A method described by Platt82 allows
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the generation of a probabilistic outcome by fitting a sigmoid function to the discriminant using
independent holdout training data. In this study, we used the corrected Platt algorithm provided
by Lin and colleagues. 83
The parameters of each kernel type were optimized on the kernel training set separately
for MSE, AUC and HL x2 values by a grid search method on the training set, using 3-fold cross-
validation.84 The sigmoid training set was used to convert discriminant results into probabilities.
The width function for the radial-based kernel ranged from 2-4 to 24 (2 -4, 2 3 2-2, etc.), and
power for the polynomial-based kernel ranged from 1 to 6 by integers. For each respective
kernel type and optimization parameter, the best kernel parameter was used to generate a model
on the entire kernel training set, and a sigmoid for discriminant conversion was generated using
the sigmoid training set. Each of the models was then applied to the respective test data set.
Statistical Evaluation
Discrimination was assessed with the area under the receiver operating characteristic. 51
Calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit X2 goodness-of-fit
782
estimates. 7 8 X2 values with 8 degrees of freedom are considered adequately calibrated for values
of 15.51 or less (corresponding to ap value >= 0.05). Pair-wise comparison between
performance measures was performed using a one-way ANOVA test for summary values with
known standard errors.
Results
A summary of test data evaluation for each model type and cross validation optimization
parameter is shown in Table 2. Each respective model parameter (p-value threshold for a
variable to stay in the model, kernel width factor, and kernel power for LR, SVM-R, and SVM-
P, respectively) and performance measure includes the mean values and 95% confidence
intervals for the respective model type.
Results of the pair-wise comparison between each optimization type of each modeling
method are shown in Table 3. The upper right half of the table contains AUC comparisons, and
the lower left half of the table contains HL 2 comparisons. p values less than 0.05 indicate a
significant difference between the pair.
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None of the LR models resulted in AUCs that were significantly different from any other
ILR model (all p > 0.05). All of the LR models had higher AUCs than the radial-based SVMs (all
p < 0.05). The LR models had significantly higher AUCs when compared to the HL x2
optimization method of SVM-P (p = 0.012, 0.012, 0.025, and 0.027), but not higher than the
AUCs from MSE or AUC methods.
None of the LR models had HL %2 values significantly different from any other LR
model (all p> 0.05). All of the radial-based and polynomial-based SVM models showed
significantly lower HL %2 values than any of the LR models (all p < 0.05). The HL X2
optimization method was superior to both the MSE and AUC methods in the radial-based SVM
models (p < 0.001). The HL %2 optimization method in both kernel types was significantly better
than all of the other model versions based on MSE and AUC, except the MSE and AUC
optimization methods of SVM-P (p < 0.05).
Model Opt Parameter Mean AUC (95% CI) HL %2 (95 % CI)
LR None 0.10 0.911 (0.905 - 0.916) 101.1 (49.4 - 152.8)
LR MSE 0.25 (0.22 - 0.28) 0.912 (0.906 - 0.917) 89.8 (53.0 - 126.7)
LR AUC 0.29 (0.26 - 0.33) 0.912 (0.906 - 0.917) 94.7 (46.0 - 143.4)
LR HL x2 0.17 (0.14 - 0.20) 0.911 (0.905 - 0.916) 99.1 (46.8 - 151.4)
SVM-R MSE 0.13 (0.08 - 0.17) 0.873 (0.874 - 0.883) 30.3 (27.9 - 32.6)
SVM-R AUC 0.28 (0.19 - 0.36) 0.894 (0.888 - 0.900) 28.5 (26.0 - 30.9)
SVM-R HL Z2 4.53 (3.47 - 5.59) 0.901 (0.895 - 0.908) 16.4 (13.4 - 19.4)
SVM-P MSE 3.09 (2.97 - 3.21) 0.912 (0.905 - 0.919) 34.1 (12.4 - 55.8)
SVM-P AUC 2.65 (2.50- 2.80) 0.915 (0.909 - 0.922) 33.5 (11.8- 55.1)
SVM-P HL 2 2.98 (2.64 - 3.31) 0.899 (0.891 - 0.907) 20.0 (15.2 - 24.8)
Table 2: Analysis of the test data by model method and cross validation optimization method. LR = backwards
step-wise Logistic Regression model, SVM-R = radial-based kernel SVM, SVM-P = polynomial-based kernel SVM.
Opt = Cross Validation optimization method. AUC = Area under the Receiver Operating Characteristic Curve. HL
2X = Hosmer-Lemeshow Goodness-of-Fit. MSE = mean squared error. For the model parameters, the values refer
to the exclusion threshold (p-value) for LR, w for SVM-R, and p for SVM-P.
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LR LR LR LR SVM-R SVM-R SVM-R SVM-P SVM-P SVM-P
(MSE) (AUC) (HL) (0.10) (MSE) (AUC) (HL) (MSE) (AUC) (HL)
0.980 0.724 0.667 <0.001 <0.001 0.014 0.997 0.393 0.012
LR (MSE) i- +- -- -
0.857 0.741 0.311 <0.001 <0.001 0.014 0.986 0.379 0.012
LR (AUC) .. . .-
0.773 0.901 0.175 <0.001 <0.001 0.032 0.756 0.239 0.025
LR (HL) -- - - - -
0.725 0.858 0.958 <0.001 <0.001 0.035 0.715 0.214 0.027
LR (0.10) + +4 -
0.002 0.009 0.010 0.007 <0.001 <0.001 <0.001 <0.001 <0.001
SVM-R (MSE) *- - 4' - T T T T T
0.001 0.008 0.008 0.006 0.301 0.004 <0.001 <0.001 0.354
SVM-R(AUC) . + t t t
<0.001 0.002 0.002 0.001 <0.001 <0.001 0.025 0.002 0.677
SVM-R(HL) .. . . X . +4 T T
0.011 0.025 0.024 0.019 0.729 0.612 0.111 0.4378 0.019
SVM-P (MSE) . + + .-
0.010 0.024 0.022 0.018 0.772 0.652 0.124 0.968 0.002
SVM-P (AUC) +. +4 +4 + 
<0.001 0.003 0.003 0.002 <0.001 0.002 0.204 0.212 0.232
SVM-P(HL) --_ -- --+-
Table 3: Summary of p values for the pair-wise comparison between different versions of the modeling methods.
The top right half of the table contains p values for AUC measurements, and the bottom left half of the table
contains p values for the HL X2measurements. LR = backwards step-wise Logistic Regression model, SVM-R =
radial-based kernel SVM, SVM-P polynomial-based kernel SVM. AUC = Area under the Receiver Operating
Characteristic Curve. HL = Hosmer-Lemeshow Goodness-of-Fit. MSE = mean squared error. Bold values are
statistically significant. T = Column-based model statistically superior. - = Row-based model statistically
superior.
Discussion
All of the models had excellent discriminatory (AUC) performance. This suggests that
the clinical data collected in this domain is able to account for the majority of risk for in-hospital
post-PCI mortality.
The LR models had superior discrimination to the SVM-R models, and also to the HL 2
optimization method of the SVM-P models. This shows that the clinical data are probably
linearly separable, and is consistent with prior studies of logistic regression in this domain. In
addition, the polynomial kernel was superior to the radial kernel in its ability to discriminate
using the MSE and AUC methods.
The MSE method is a common optimization score in regression model development, and
the AUC and HL X2 values were experimental optimization parameters. To our knowledge, there
have been no reports on their use for optimizing variable selection. Discrimination in the LR
models was insensitive to the optimization method. The SVM-R models showed a performance
improvement with AUC over MSE, and with HL X2 over both AUC and MSE. The SVM-P
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showed a performance improvement with both the MSE and AUC methods over the HL X2
method.
Calibration was significantly higher in both of the SVM model types compared to the LR
models. Different optimization methods did not significantly impact the LR models. However,
the HL X2 optimization method provided significant improvement for the SVM-R models.
None of the models achieved an upper 95% CI lower than 15.51, revealing that at least a portion
of each model type failed to adequately calibrate. However, this is a common finding in other
studies that evaluated risk models on a large volume of data sets. This happens because small
numbers of models with large HL 2 values skew the distribution.
When a model is generated, a balance must be maintained between overfitting and
underfitting. Overfitting improves the fit of the model on the training data but reduces its
performance on external data. Underfitting generalizes the fit of the model by reducing the
complexity of the fit on the training data in order to improve classification or regression results
to other data sets. In these data, the AUC and MSE optimization methods significantly overfit
the SVM-R models, as shown by the large difference between the mean width factors of HL X2
and the other two optimization strategies. In GIST, a decrease in the width factor is associated
with an increase in the fit to the training data. However, the model parameters were not
substantially different between optimization types for LR or SVM-P.
The primary limitations of this study are the lack of manual manipulation in the modeling
process, although this was required by the methodology. In the single model development
process, optimization in terms of model parameters, introduction of interaction terms, and feature
selection would be manually performed by further optimizing a cross-validation score (MSE,
AUC, etc.) if the discrimination was not deemed good or the calibration was inadequate in the
training sample.
The parameter selection process used a 3-fold CV method, and the model evaluation used
a separate testing sample over 100 randomized data sets. This is related to the nested stratified
10-fold CV method as described by Statnikov and colleagues.85 The small number of training
folds (or inner loop) were utilized because of high computational times of GIST in the relatively
large data sets. This may have increased the variance of the scores in the parameter optimization
methods, although the large number of data points in each fold likely minimized this problem.
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Overall, both the polynomial and radial-based SVMs achieved better calibration than the LR
models. Experimentation with different scoring methods used to select parameters for model
generation revealed that the regular method of MSE scoring performed as well as the others for
LR. However, the HL X2 method achieved the best results for both discrimination and
calibration for the radial-based kernels, but improved calibration performance at the expense of
discrimination for the polynomial-based kernels. This tradeoff requires further exploration.
Use of support vector machine risk models to promote adequate calibration and produce
more accurate individualized prognostic estimates for patients is supported by this preliminary
study. Future work will include investigating other calibration indices, recalibration methods,
and further evaluation of this method for inclusion in an automated real-time safety monitoring
system.
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Chapter 3: Design and implementation of an Automated Real-Time Safety
Monitoring Application
Background
Minimizing harm to patients and ensuring their safety are cornerstones of any clinical
research effort. Safety monitoring is important in every stage of research related to a new drug,
new medical device, or new therapeutic procedure. This type of monitoring of medical devices,
under the auspices of the Food and Drug Administration (FDA), has undergone major changes
over the last several decades. -4 These changes have largely been due to a small number of
highly publicized adverse events.5- 13 The FDA's task is complex; the agency regulates more
than 1,700 types of devices, 500,000 medical device models and 23,000 manufacturers. 3 ' 6 17, 19,
20, 22, 63 In pre-marketing clinical trials, rare adverse events may not be discovered due to small
sample sizes and biases towards healthier subjects.14 The FDA must balance this concern with
the need to deliver important medical advances to the public in a timely fashion. In response to
this, the FDA has shifted some of its device evaluation to the post-market period, allowing new
devices to reach the market sooner.' 5 This creates the potential for large numbers of patients to
be exposed to a new product in the absence of long-term follow-up data, and emphasizes the
need for careful and thorough post-marketing surveillance.'6
The current FDA policies in this area include a heterogeneous mix of voluntary and
mandatory reporting.1 6, 14, 17-22 Voluntary reporting of adverse events creates limitations in
significant event-rate recognition through underreporting bias, and highly variable reporting
quality. 14 Several state and federal agencies have implemented mandatory reporting for medical
devices for specific clinical areas, and national medical societies are making strides to
standardize data element definitions and data collection methods within their respective
2366domains.2 64 6 Continued improvements in the quality and volume of reported data have
created opportunities for timely and efficient analysis and reporting of alarming trends in patient
outcomes.
Non-medical industries (Toronado, HGL Dynamics, Inc., Surrey, GU, WinTA, Tensor
PLC, Great Yarmouth, NR) have been using a variety of automated statistical process control
(SPC) techniques for quality control purposes for many years.66 -68 These systems rely on
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automated data collection, and use standard SPC methods of varying rigor. 24 However,
automated SPC monitoring has not been widely deployed in the medical domain due to a number
of constraints: (a) historically, automated data collection could usually only be obtained for
objective data such as laboratory results and vital signs; (b) much of the needed information
about a patient's condition is subjective and may be available only in free text in the medical
record; and (c) medical source data, due to heterogeneity of clinical factors, typically has more
noise than industrial data, and standard industrial SPC metrics may not be directly applicable to
medical safety monitoring.
Within the medical domain, the most closely related clinical systems that have been
developed to date are those in clinical trial monitoring for new pharmaceuticals. A variety of
software solutions (Clinitrace, Phase Forward, Waltham, MA; Oracle Adverse Event Reporting
System [AERS], Oracle, Red Shores, CA; Trialex, Meta-Xceed, Inc., Freemont, CA; Netregulus,
Netregulus, Inc., Centennial, CO) have been created to monitor patient data relevant to the study
trial. These systems rely on standard SPC methodologies, and can provide real-time data
monitoring and analysis through internal data standardization and collection for the trial.
However, the focus of these systems is on real-time data aggregation and reporting to the FDA.
The increasing availability of detailed electronic medical records and structured clinical
outcomes data repositories may provide new opportunities to perform real-time surveillance and
monitoring of adverse outcomes for new devices and therapeutics beyond the clinical trial
environment. However, the specific monitoring methodologies that balance appropriate adverse
event detection sensitivity and specificity remain unclear.
In response to this opportunity, we have developed the Data Extraction and Longitudinal
Time Analysis (DELTA) system, and explored both standard and experimental statistical
techniques for real-time safety monitoring. A clinical example was chosen to highlight the
functionality of DELTA, and to provide an overview of its potential uses. Interventional
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cardiology was chosen because the domain has a national data field standard,2 3 a recent increase
in mandatory case reporting from state and federal agencies, and recent device safety concerns
publicized by the FDA.
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Methods
System General Requirements
The DELTA system was designed to provide real-time monitoring of clinical data during
the course of evaluating a new medical device, medication, or intervention. The system was
designed to satisfy five principal requirements. First, the system should accept a generic dataset,
represented as a flat data table, to enable compatibility with the broadest possible range of
sources. Second, the system should perform both prospective and retrospective analysis. Third,
the system should support a variety of classical and experimental statistical methods to monitor
trends in the data, configured as analytic modules within the system, allowing both unadjusted
and risk-adjusted safety monitoring. In addition, the system should support different
methodologies for alerting the user. Finally, DELTA should support an arbitrary number of
simultaneous datasets, and an arbitrary number of ongoing analyses within each dataset. That is,
DELTA should "track" multiple outcomes from multiple data sources simultaneously, thus
making it possible for DELTA to serve as a single portal for safety monitoring for multiple
simultaneous analyses in an institution.
Source Data and Internal Data Structure
A flat file representation of the covariates and clinical outcomes serves as the basis for all
analyses. In addition, a static data dictionary must be provided to DELTA to allow for parsing
and display of the source data in the user interface. Necessary information includes whether
each field is going to be treated as a covariate, an outcome, and whether it is discrete or
continuous.
The system uses a SQL 2000 server (Microsoft Corp., Redmond, WA) for internal data
storage, importing all clinical data and data dictionaries from source databases at regular time
intervals. This database also stores system configurations, analysis configurations, and results
that are generated by DELTA at the conclusion of a given time period. The user interface is
web-based, and uses a standard tree menu format for navigation. DELTA's infrastructure and
external linkages are shown in Figure 1.
Security of patient data is currently addressed through record de-identification steps69
performed to the fullest extent possible while maintaining the necessary dataset granularity for
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Figure 1: Overall DELTA infrastructure and an example external data source. SPC: Statistical Process Control; LR:
Logistic Regression; BUS: Bayesian Updating Statistic.
the risk adjustment models. The system is hosted on the Partners Healthcare intranet, a secure
multi-hospital network, accessible at member sites or remotely through VPN.
Statistical Methods
DELTA utilizes a modular approach to statistical analysis that facilitates further
expansion. DELTA currently supports three statistical methodologies: statistical process control
(SPC), logistic regression (LR), and Bayesian updating statistics (BUS). Discrete risk
stratification is supported by both SPC and BUS. Periodic and cumulative analysis of data is
supported by SPC and LR, and only cumulative analysis is supported by BUS.
Risk stratification is a process by which a given sample is subdivided into discrete groups
based on predefined criteria. This process is used to allow providers to quickly estimate the
probability of an outcome for a patient. Statistically, the goal of this process is to create a
meaningful separation in the data to allow concurrent and potentially different analyses to be
performed on each subset. Criteria are selected based on prior data, typically derived from a
logistic regression predictive model, and the relative success of this stratification can be
determined by a stepwise increase in the incidence of the outcome in each risk group. The LR
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method does not offer discrete risk stratification because it incorporates risk stratification on a
case level.
Retrospective data analyses traditionally use the entire data set for all calculations.
However, in real time data analysis, it is of interest to monitor both recent trends and overall
trends in event rates. Evaluation of recent trends will intrinsically have reduced power, because
of the reduced sample size, to detect true, significant shifts in event rates. However, such
monitoring may serve as a very useful 'first warning' indicator when the cumulative event rate
may not yet cross the alerting threshold. This type of alert is not considered definitive, but can
be used to encourage increased monitoring of the intervention of interest and heighten awareness
of a potential problem. In DELTA, these recent data analyses are termed 'periodic', and can be
configured to be performed on a monthly, quarterly, or yearly basis.
SPC is a standard quality control method in non-medical industrial domains. This
method compares observed event rates to static alerting boundaries developed from previously
published or observed empirical data. Each industry typically requires different levels of rigor in
alerting, and selection of confidence intervals (or number of standard errors) establishes this
benchmark. In the medical industry, the 95% confidence interval (CI) is considered to be the
threshold of statistical improbability to establish a 'true' difference. In DELTA, the 95% CI of
proportions by the Wilson method is used to calculate the alerting boundaries for all statistical
methods.70 The proportion of observed events are then compared to these static boundaries, and
alerts are generated if they exceed the upper CI boundary. DELTA's SPC module is capable of
performing event rate monitoring on multiple risk strata provided that criteria for stratification
and benchmark event rates are included for each risk stratum. This method supports comparison
of benchmark expected event rates with cumulative and periodic observed event rates.
While simple and intuitive, the SPC methodology does not support case-level risk
adjustment. It is also dependent on accurate benchmark data, which may be limited for new
procedures or when existing therapies are applied to new clinical conditions.70
Logistic regression is a non-linear modeling technique used to provide a probability of
an outcome on case-level basis. Within DELTA, the LR method allows for continuous risk-
adjusted estimation of an outcome at the case level. The LR model must be developed prior to
the initiation of an analysis within DELTA, and is mostly commonly based on previously
published and validated models.
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Alerting thresholds are established by using the LR model's expected mortality
probability for each case. These probabilities are then summated in both periodic and
cumulative time frames to determine the 95% confidence interval (CI) of the event rate
proportion by the Wilson method. Alerts are generated if the observed event rate exceeds the
upper bounds of the 95% CI of a given boundary. This method provides accommodation for
high risk patients by adjusting the alerting boundary based on the model's expected probability
of death. This is can be very useful in when outcome event rates vary widely with patient co-
morbidities. A limitation of this method is that the alerts become dependent on the
discrimination (measure of population prediction accuracy) and calibration (measure of small
group or case prediction accuracy) of that model.
BUS is an experimental methodology pioneered in non-healthcare industries.72 This
method incorporates Bayes' theorem7 3 into a traditional SPC framework by utilizing prior
observed data to evolve the estimates of risk. Alerting boundaries are calculated by two
methods, both of which are considered cumulative analyses only. The first method includes
previous current study data with the prior data used in the SPC method to calculate the 95% CI
of the event rate proportion by the Wilson method. This means that the alerting boundary shifts
during the course of real-time monitoring due to the influence of the earlier study data.
The other alerting method is based on the evolution of the updated risk estimates
represented as probability density functions (PDF). In each period, a new PDF is generated
based on the cumulative study event rate and baseline event rate. Alerting thresholds are
generated by the user specifying minimum percent amount of overlap of the two distributions (by
comparison of central posterior intervals).7 4 The first comparison PDF is the initial prior PDF,
and the second is the previous period's PDF. BUS supports discrete risk stratification.
This method was included in DELTA because it tends to reduce the impact of early
outliers in data and complements the other monitoring methods used in the system. It also may
be particularly helpful in situations in which limited pre-existing data exist. However, the
method is dependent on accurate risk strata development, and on the methods used for weighting
of the prior data in the analysis.
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User Interface
The user interface is provided via a web browser and was developed in the Microsoft
.NET environment, running Microsoft IIS 5.0 Web Server (Microsoft Corp., Redmond, WA).
Each data set is represented as a separate folder on the main page, and all analyses for that set are
nested under that folder (see Figure 2). At the initiation of an analysis, the user designates the
analysis period and starting and stopping dates, selects the statistical module, and selects the
outcome of interest. Data filters can be applied to restrict the candidate cases for analysis.
Covariates used for risk stratification are selected. Lastly, periodic and cumulative alerts for the
statistical method selected can be activated or suppressed based on user preferences. An analysis
configuration can be duplicated and modified for convenience in configuring multiple statistical
methods to concurrently monitor a data source.
The results screen of DELTA serves as the primary portal to all tables, alerts, and graphs
generated from an analysis. Tabular and graphical outputs of the data and specific alerting
thresholds by risk strata are available, and an export function is included to allow researchers to
perform further evaluation of the data.
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Results
- 4 DeltaSystem
Active Alerts
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- AllDataSets
- BWH Data Set
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Figure 2: DELTA Screenshot showing the results menu screen of the SPC clinical example described in Section 4.
The main menu is displayed on the left, and the analysis menu is displayed above the viewing area.
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Clinical Example
As an example of the application of DELTA to real-world data, an analysis of the in-
hospital mortality following the implantation of a drug-eluting stent was performed. The cardiac
catheterization laboratory of Brigham and Women's Hospital has maintained a detailed clinical
outcomes database since 1997 for all patients undergoing percutaneous coronary intervention,
based on the American College of Cardiology National Cardiovascular Data Repository (ACC-
NCDR) data elements.39
For risk stratification, the University of Michigan risk prediction model33 was used since
it provides a concise method of comparing all three of DELTA's statistical methods using one
reference for prior experience. The previous experience of event rates for all risk strata from this
work is listed in Appendix A. A logistic regression model with risk stratification scores are
listed in Appendix B. The logistic regression model developed from the data was used to create
a discrete risk scoring model. Based on the mortality of patients in the study sample at various
risk scores, these data were divided into three discrete risk categories, and the compositions of
those categories are listed in Appendix B.
A total of 2,270 drug-eluting stent (DES) cases were performed from July 01, 2003, to
December 31, 2004, at our institution, and the outcome in terms of in-hospital mortality was
analyzed. These data were retrospectively evaluated in monthly periods for each of the three
statistical methodologies. There were a total of 27 observed deaths (unadjusted mortality rate of
1.19%) during the study. Local institutional IRB approval was obtained. Risk stratification of
these cases by the University of Michigan model is listed in Table 1, and demonstrates increasing
in-hospital mortality risk with 0%, 0.9%, and 23% mortality risk in the low, medium, and high
risk strata respectively.
An alternative data set was generated by taking the clinical data above and changing the
procedure date from the 8 cases with the outcome of interest in the last 5 periods. The
procedures dates were changed by random allocation into one of the first 13 periods. The
duration of the monitoring was then shortened to 13 periods. This was done to illustrate alerts
when cumulative event rates clearly exceeded established thresholds. The overall event rate for
this data set is 1.71% (27/1583), and the risk stratified event rate was 0% (0/446), 1.3%
(14/1095), and 31%(13/42) for the low, medium, and high risk strata, respectively.
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Risk Strata Sample Events Event Rate
Low 641 0 00.00%
Mod 1573 14 00.89%
High 56 13 23.21%
Table 1: Multiple Risk Strata SPC.
Results
Statistical Process Control
The single risk stratum SPC was configured with no risk stratification covariates. The
static alert boundary was a 2.07% (upper 95% CI of 100/5863). Periodic evaluations ranged
fromn 0% to 4.5%. Period 4 exceeded the boundary with a 3.4% (5/148) event rate, and period 10
with a 4.5% (5/110) event rate. Cumulative event rates ranged from 0.9% (2/213) to 1.7%
(10/587). No cumulative evaluations had an event rate that exceeded the boundary. The
cumulative evaluation is depicted graphically in Figure 3.
Periodic evaluations of the alternative data set ranged from 0% to 4.7%. Period 4
exceeded the boundary with a 4.7% (7/150) event rate, period 7 with a 2.6% (3/117) event rate,
period 8 with a 2.6% (3/117) event rate, and period 10 with a 4.5% (5/110) event rate.
Cumulative event rates ranged from 0.9% (2/213) to 2.4%(12/490). Periods 4 through 11 had
event rates exceeding the 2.07% threshold and generated alerts, and ranged from 2.1% to 2.4%.
Alerting thresholds were calculated for the low, medium, and high risk strata by using the
upper 95% CI of the proportion of the event rates of each stratum in the University of Michigan
data. The thresholds were 0.3% (1/1820), 1.7% (50/3907), and 44% (49/136), respectively.
There were no events in the low-risk stratum, and no alerts were generated. In the
moderate-risk stratum, the periodic observed event rates ranged from 0% to 2.7%. The alerting
boundary was exceeded with rates of 2.7% (2/75) in period 5, 2.6% (2/78) in period 10, and
1.9% (2/108) in period 18. The cumulative observed event rates ranged from 0.7% to 1.3%, and
never exceeded the upper alert boundary. In the high-risk stratum, the periodic observed event
rates ranged from 0% to 100%. The alerting boundary was exceeded with rates of 100% in
periods 1 (1/1), 7 (1/1), and 10 (3/3), and by a rate of 50% (4/8) in period 4. The cumulative
observed event rates ranged from 16.7% to 100%. The alerting boundary was exceeded by a rate
of 100% (1/1) in period 1.
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Evaluation of the alternative data set was performed periodic and cumulative alerts.
There were no events in the low-risk stratum, and no alerts were generated. In the moderate-risk
stratum, the periodic observed event rates ranged from 0% to 3.6%. The alerting boundary was
exceeded with rates of 3.6% (3/84) in period 3, 2.1% (2/95) in period 4, 2.7% (2/75) in period 5,
2.5% (2/81) in period 7, and 2.6% (2/78) in period 10. The cumulative observed event rates
ranged from 0.7% to 2.0%, and exceeded the alerting boundary in periods 3 through 11. In the
high-risk stratum, the periodic event rates ranged from 0% to 100%. The alerting boundary was
exceeded with rates of 100% in periods 1 (1/1), 7 (1/), and 10 (3/3), and by a rate of 55.6% (5/9)
in period 4. The cumulative observed event rates ranged from 16.7% to 100%. The alerting
boundary was exceeded by a rate of 100% (1/1) in period 1.
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Figure 3: Single-stratum SPC graph showing the cumulative observed event rates versus the static alerting threshold
(expected rates) with 95% confidence intervals.
Logistic Regression
Alerting thresholds were calculated on a periodic basis using the expected probability of
death for the cases in their respective periods, and the 95% upper CI ranged from 4.9%
(1.02/112) to 7.1% (2.51/110). Cumulative-based upper alerting boundaries ranged from 2.3%
(29.86/1835) to 5.7% (1.66/115). The overall expected cumulative event rate was 1.75%
(39.7/2270).
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Periodic event rates ranged from 0% to 4.5%, and no alerts were generated. The two
highest periodic event rates of 3.4% (5/148) in period 4 and 4.5% (5/110) in period 10 had upper
alerting boundaries of 5.8% (2.98/148) and 7.1% (2.51/110), respectively. Cumulative event
rates ranged from a 0.9% (2/213) to 1.7% (10/587) event rate, and the cumulative upper 95% CI
was well above the observed event rate throughout the evaluation and are shown in Figure 4.
Alerting thresholds for the alternative data set based on the upper 95% CI ranged from
4.9% (1.02/112) to 7.5% (3.2/117) in the periodic analysis, and from 2.6% (28.17/1583) to 5.7%
(1.66/115) in the cumulative analysis. The overall expected event rate was 1.78% (28.17/1583).
Periodic event rates ranged from 0% to 4.7%, and no alerts were generated. The two
highest periodic event rates of 4.7% (7/150) in period 4 and 4.5% (5/110) in period 10 had upper
alerting boundaries of 6.2% (3.56/150) and 5.1% (2.51/110). Cumulative event rates ranged
from 0.9% (2/213) to 2.4% (12/490), and were well below the alert boundaries through the
evaluation.
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Figure 4: Logistic Regression graph showing the cumulative observed event rate versus the cumulative expected
event rate with 95% CI.
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Bayesian Updating Statistics
The upper alert boundary varied from 0.2% to 0.3%, from 1.5% to 1.7%, and from 40.2%
to 44.4% in the low, medium, and high risk strata, respectively. From all strata, the only alert
generated was in the high risk stratum period 1 with an observed event rate of 100% and an
upper alert boundary of 44.4% (49/136).
There was a trend towards lower event rates in the PDFs of all risk strata, as illustrated
for the high-risk stratum cases in Figure 5. At no time in any strata did the posterior confidence
interval overlap fall below the user-specified 80% criteria.
The upper alert boundaries in the alternative data set were the same as the real data set.
However, in the moderate-risk stratum, the observed event rates of 1.73% (4/231) in period 3,
1.84% (6/325) in period 4, 2.0% (8/400) in period 5, 1.73% (10/576) in period 7, and 1.71%
(14/818) in period 10% exceeded the alert boundaries that ranged from 1.65% to 1.74% for those
periods.
The trend towards lower event rates in the PDFs of all risk strata in the real data set was
not found in the alternative data set. At no time in any strata did the posterior confidence
interval overlap fall below the user-specified 80% criteria.
14
12
10
B
6
4
2
0
Pfior
; 2003M07-JuI
2003M08-Aug
2003M09.Sep
2003M1 0-Oct
2003M1 I-Nov
L,- 2003MI 2-Dec
2004M01-Janl
- 2004M02-Feb
L-~ 2004M03-Mar
2004MO4-Apr
2004M06-Jun
- 2004MO7-Jui
2004MO8-Aug
2004M09 -Sep
-2004M110-Oct
' 2004M11-Nov
2004M1 2-Dec
Figure 5: Bayesian Updating Statistics Probability Density Functin (BUS PDF) evolution for
high-risk cases, by period.
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Discussion
The DELTA system satisfied all pre-specified design requirements, and performed all
analyses and graphical renderings within 2 seconds each on the hospital intranet.
The SPC method triggered periodic alerts in both single and multiple risk strata analyses.
This method also triggered the first period's cumulative alert in the multiple risk strata, but this
can be considered a periodic equivalent alert. Otherwise, there were no cumulative event rate
alerts detected by the SPC method. The LR method generated no alarms in either the periodic or
cumulative evaluations. The BUS method generated an alert only in the first period of the high-
risk stratum. While all BUS alerts are considered cumulative, the alert was generated from one
case with a positive outcome for that period.
The alternative data set event rate was elevated manually to generate alarms. The single
stratum SPC method alerted to event rates exceeding the threshold for periods 4 through 11. The
multi-strata SPC method revealed that the event rate rise of concern was in the moderate risk
group, alerting from periods 3 through 11. The LR method generated no periodic or cumulative
alerts in the alternative data set. The BUS method agreed that the elevation was primarily of
concern in the moderate risk stratum by generating cumulative alerts in periods 3, 4, 5, 7, and 10.
Periodic alerts are very sensitive measures of elevated event rates, but generally lack the
statistical power to make a conclusive decision about the safety of a device. These alerts would
serve to heighten surveillance and possibly reduce the interval of evaluation for the new device,
but would not in of themselves be sufficient to recommend withdrawal of the device. The
discrepancy between SPC and LR periodic alerting was because LR attempts to adjust the
alerting threshold based on the expected outcome of a given case. If there were a rise in the
event rate for a period, SPC would trigger an alert as the rate exceeds the static threshold.
However, if the LR model expected the cases to have that outcome, then the method would likely
not alert as the alert threshold would be adjusted based on that expectation. The cumulative
alerts for this analysis were consistent across statistical methods, and the alerts in the first period
were due to a very low number of examined cases. In the alternative set, the LR method has no
cumulative alerts, and this could be due to the fact that the events were expected by the model.
In phase 3 randomized controlled trials, there is no previous data to use as a benchmark,
and a common method of determining the threshold of stopping the trial is to initially place the
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threshold at a very statistically improbably number (such as 5 or 6 standard errors from an
estimated allowable rate) and gradually reduce the allowable error as the volume of data grows.
The allowable rates are generally established by expert consensus and are manually generated on
a trial by trial basis.
The benefits of incorporating prior information into the development of alerting
thresholds include the ability to develop and establish explicit rules for alerting thresholds. This
methodology could then be applied in an objective manner to a wide variety of monitoring
applications. This removes the need for an expert consensus to develop the thresholds.
However, this objective methodology has limitations. The accuracy of the alerting boundaries is
dependent on the source data. In the case of this clinical example, the University of Michigan
BMS mortality data and model was established as the benchmark. DELTA then considered
mortality event rates statistically significantly above that baseline to be abnormal and of concern.
This becomes important when assessing the external validity of the benchmark data with regards
to applicability in a different patient population. In addition, applying multiple concurrent
statistical methodologies to a monitoring process is meant to guard against specific
vulnerabilities one methodology might have to these type of confounding.
SPC is only concerned with the overall event rate in the benchmark source population to
establish alerting boundaries, and these are static throughout the analysis. This is the least
sensitive to subpopulation variations between the study and baseline populations. Including
multiple risk strata in the analysis increases the sensitivity to finding problems in a specific risk
group but requires the user to ensure that the study subpopulations using the risk stratification
criteria are representative of the source subpopulations. Similar proportions and relative event
rate risks between the source data and study data supports the use of stratification in this clinical
example.
LR is the most susceptible method to population differences because it provides a case
level estimation based on a number of risk factors. In a number of studies these models suffer
degraded predictive ability at the case level in disparate populations and as the time from the
model's development increases.74 In the example, the population's event rate was 1.19% and the
LR model's expected event rate was 1.75%. This shows that the LR model over-predicted
mortality for this population.
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BUS carries many of the same benefits and drawbacks of using the aggregate source
population's event rate to establish alerting thresholds, but allows for the movement of these
thresholds by changing study event rates. This method is the most capable in determining a
significant shift in a short period of time.
Overall, the results of the example analysis support that the in-hospital mortality
following implantation of DES was acceptably low over the time period studied when compared
with the University of Michigan BMS benchmark data. The prototype system currently in use at
Brigham and Women's Hospital Cardiac Catheterization Laboratory is in a testing and
evaluation phase, and as such, clinicians do not consult the system directly. An evaluation of the
current user interface will be conducted to assess DELTA's acceptability in the clinical
environment by different health care providers. However, the preliminary results of our testing
are encouraging: the DELTA system shows promise in filling a need for automated real-time
safety monitoring in the medical domain, and may be applicable to routine safety monitoring for
hospital quality assurance, and monitoring of new drugs and devices.
Risk Strata Risk Score Sample Deaths Death % Upper 95% CI
Low 0-1.49 1820 1 0.015 0.03
Moderate 1.5-5.49 3907 50 1.28 0.017
High 5.50+ 136 49 36.0 0.443
TOTAL 5863 100 1.71 0.0207
Appendix A: Summary of the sample population and outcome of interest (death) per risk strata in the University of
Michigan data sample.46
Covariate LR [3 Odds Ratio Risk Score
MI within 24 hours 1.03 2.8 1
Cardiogenic Shock 2.44 11.5 2.5
Creatinine > 1.5 mg/dL 1.70 5.5 1.5
History of Cardiac Arrest 1.29 3.65 1.5
Number of Diseased Vessels 0.44 1.54 0.5
Age 70-79 0.81 2.24
Age >= 80 0.97 2.65
Age >= 70 1.0
LV Ejection Fraction <50% 0.51 1.66 0.5
Thrombus 0.52 1.67 0.5
Peripheral Vascular Disease 0.46 1.57 0.5
Female Sex 0.59 1.82 0.5
Intercept -7.20
Appendix B: University of Michigan Covariates with Beta Coefficients for the logistic regression model and Risk
Scores for the discrete risk stratification. 4 6 Intercept is the LR model equation intercept.
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Chapter 4: Sensitivity Analysis of SPC and Bus Alerting Thresholds
Background
In a prior work,7 5 we established the feasibility of a real-time automated monitoring
system, and evaluated implementations of Statistical Process Control (SPC)76 and Bayesian
Updating Statistics (BUS)7 7 for this application on actual clinical data in the domain of
Interventional Cardiology. However, sensitivity analyses to determine the independent and
relative performance of these methodologies has not been established, and is required for the
subsequent use of this tool.
The purpose of this study is to compare alerting thresholds for SPC and BUS methods
using local Interventional Cardiology clinical data.
Methods
Study Setting
Brigham & Women's Hospital (BWH) is a 720 bed academic teaching hospital in
Boston, Massachusetts. BWH's cardiac catheterization laboratory has maintained a detailed
clinical outcomes database since 1997 for all patients undergoing percutaneous coronary
intervention (PCI). The database is compliant with the domain's national data element standard,
based on the American College of Cardiology National Cardiovascular Data Repository (ACC-
NCDR) guidelines, and provides detailed mandatory quarterly reports to the state (MASS-DAQ).
Subjects
All angioplasty procedures performed between January 01, 2002 and December 31, 2004
were selected for inclusion in this study. The outcome of interest was a major adverse cardiac
event (MACE). This is an aggregate outcome consisting of death, post-procedural myocardial
infarction, or a repeat vascularization (PCI or bypass surgery). The actual overall outcome event
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rate for the sample was 6.5% (403/6175). This study was approved by the Partners Institutional
Review Board.
Alerting Thresholds
The Wilson method70 for the 95% confidence interval of a proportion was selected to
generate the appropriate alerting thresholds. The equation is shown here:
2np+z 2 + (z 2 +4npq)
Z22(n+z 2)
where p is the proportion, q is 1 - p, z is Standard Normal deviate associated with the two-tailed
probability a, and n is the sample size. The SPC alerting method uses the Wilson method to
generate a static alerting threshold based on the expected number of events and cases.
The BUS method, however, incorporates past observed events and number of cases into
the baseline prior expected events and cases to generate a posterior alerting threshold for each
new time period. This updating process uses the beta inverse function on the updated baseline to
find the 97.5% tail of the central posterior distribution.7 7
Observed and Expected Event Rate Simulation
A range of identical baseline alerting thresholds were generated for both SPC and BUS
methods. These expected event rates were constructed by varying both the overall event rate and
the number of cases (denominator). The overall event rates were manually set to be 0.005, 0.05,
or 0.5, and a range of magnitudes (statistical power) for each of these event rates was established
by varying the denominator by starting with 10 an doubling up to 1,000,000. In addition, 100,
1000, 10000, 100000, and 1000000 were evaluated to provide "rounded" denominators for
method comparisons. Using this method, 21 levels of denominators were generated for each
overall event rate (10, 21, 44, etc.).
A variety of overall sample observed event rates were needed to perform the evaluation.
In order to preserve the periodic outcome event rate fluctuations, a risk model to predict the
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likelihood of MACE in the clinical data was developed. All variables that were significantly
associated with the outcome from prior studies were selected for inclusion. A logistic regression
model was developed using a backwards stepwise technique (threshold 0.15) with SAS 9.1
(Cary, NC).71 Discrimination of the model was measured by the Area Under the Receiving
Operating Characteristic (AUC)5' and was 0.662. This is somewhat expected because of the
composite end-point, and a prior LR model for MACE at this institution had an ROC of 0.74.56
Calibration of the model was adequate using the Hosmer-Lemeshow goodness-of-fit test.7 The
Chi2 was 5.662 with 8 degrees of freedom, and p=0.6851. External validity was not assessed
because the model was intended for use only with the development data. The model is shown in
Table 1.
The probability of MACE for each case in the data set was generated with the resulting
LR model. Overall data set event rates were set by applying a probability cutoff to enforce the
appropriate proportion of cases to be positive outcomes. All cases with a probability above this
cutoff received a simulated outcome of 1, and all those below received an outcome of 0.
Two sets of observed event rates were generated for each of 21 denominator levels of
three expected event rates (0.5, 0.05, and 0.005). The "fine" variation in observed event rates
varied from +/- 10% by 1% increments of the expected event rate. For example, for the 50%
(0.5) event rate, the "fine" observed event rate variation ranged from 0.4 to 0.6 in increments of
0.01 (0.4, 0.41, 0.42, etc.). The "coarse" variation in observed event rates varied from +/- 90%
by 10% increments of the expected event rate. For example, in the 5% (0.05) expected event
rate, the observed event rates varied from 0.005 to 0.095 (0.05, 0.1, 0.15, etc.).
Parameter 3 Coefficient Standard Error p
Intercept -5.4657 0.4769 <0.001
IABP 0.6362 0.1080 <0.001
Age (in years) 0.0183 0.0046 <0.001
PCI Case 1.1344 0.3677 0.002
Shock on Presentation 0.9055 0.2647 0.001
Diabetes 0.2724 0.1133 0.016
Chronic Renal Insufficiency 0.3845 0.1990 0.053
Left Anterior Descending 70% Block 0.3043 0.1120 0.007
Emergent Case 0.5709 0.1422 <0.001
Salvage Case 1.8571 0.4160 <0.001
Prior Myocardial Infarction -0.2403 0.1250 0.055
Table 1: Logistic Regression model for the outcome of MACE in the clinical data.
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Statistical Analysis
The simulation protocol produced a total of 120 data sets (19 "coarse" and 21 "fine" for
each expected event rate). The data was analyzed using both the SPC and the BUS methods to
generate a number of alerts fired by each method over the first 24 of 36 months. The final
cumulative 3 6th month data was used to determine whether or not the alarm should have fired
(gold standard). No assumption was made that one method was superior to the other, so the
number of alarms of each method was measured with respect to the final 36 th month alarm status
of each method. Analysis was performed with Analyze-It (Version 1.73, Leeds, England) which
uses the non-parametric method of ROC calculation described by Beck and colleagues.79
Results
The results of the "coarse" analysis of SPC and BUS alerting methodologies for the 0.5%
expected event rate showed an AUC of 0.999 and 1.000 for SPC and BUS, respectively. These
results are shown in Table 2. Cross-analysis also showed AUCs of 0.999 for both methods. The
excellent AUCs were retained for each method in the 5% expected event rate with 1.000 and
0.999 for SPC and BUS, respectively. The BUS alerts and the SPC final alert showed good
discrimination at 0.997. While the difference was not statistically significant, the SPC alerts
compared to the BUS final alerts showed a relative decrease in AUC with 0.978. Finally, for the
50% expected event rate, significantly decreased AUCs are noted for all analyses. The SPC and
BUS methods showed AUCs of 0.950 and 0.954, respectively. The SPC alerts with the BUS
final alerts showed an AUC of 0.881, and the BUS alerts with the SPC final alerts showed an
AUC of 0.939. The performance of the SPC with the BUS final alert was significantly worse
than the BUS with the SPC final alert and confirmed a trend suggested in the 5% expected event
rate.
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Alarm Type True Alert Type Base Rate (%) AUC
SPC SPC 50 0.950 (0.916 - 0.984)
SPC BUS 50 0.881 (0.833 - 0.928)
BUS BUS 50 0.954(0.924 - 0.984)
BUS SPC 50 0.939 (0.902 - 0.975)
SPC SPC 5 1.000 (1.000 - 1.000)
SPC BUS 5 0.978 (0.957 - 0.998)
BUS BUS 5 0.999 (0.998 - 1.000)
BUS SPC 5 0.997 (0.992 - 1.000)
SPC SPC 0.5 0.999 (0.996 - 1.000)
SPC BUS 0.5 0.999 (0.997 - 1.000)
BUS BUS 0.5 1.000 (1.000 - 1.000)
BUS SPC 0.5 0.999 (0.997 - 1.000)
Table 2: Comparison of AUCs for each of the three baseline event rates (0.5%, 5%, and 50%) and "broadly" varied
observed rates. between the number of alerts for SPC and BUS (Alarm Type) and the final 36 month alarm status
for SPC and BUS (True Alert Type).
When both methods were evaluated in an identical manner with the "fine" data sets to
determine performance and differences within smaller magnitude event rate deviations, the
trends of the "coarse" data were preserved, and are shown in Table 3. All analyses and cross-
analyses for the SPC and BUS methods in the 0.5% and 5% expected event rates ranged from
0.997 to 1.000 and were not significantly different from one another. However, the 50%
expected event rate, similar to the "coarse" data sets, showed significant decreases in AUCs.
The SPC and BUS AUCs were 0.957 and 0.960, respectively. Cross-analysis of the SPC and
BUS methods showed AUCs of 0.916 and 0.959, respectively. The SUC to BUS AUC was
significantly lower than any of the others, and was consistent with the "coarse" data analysis.
Alarm Type True Alert Type Base Rate (%) AUC
SPC SPC 50 0.957 (0.938 - 0.976)
SPC BUS 50 0.916 (0.891 - 0.942)
BUS BUS 50 0.960(0.943 - 0.978)
BUS SPC 50 0.959 (0.941 - 0.977)
SPC SPC 5 1.000 (1.000 - 1.000)
SPC BUS 5 0.999 (0.998 - 1.000)
BUS BUS 5 1.000 (0.999 - 1.000)
BUS SPC 5 0.998 (0.996 - 1.000)
SPC SPC 0.5 0.994 (0.990 - 0.999)
SPC BUS 0.5 0.997 (0.993 - 1.000)
BUS BUS 0.5 0.997 (0.993 - 1.000)
BUS SPC 0.5 0.997 (0.993 - 1.000)
Table 3: Comparison of AUCs for each of the three baseline event rates (0.5%, 5%, and 50%) and "narrowly"
varied observed rates. between the number of alerts for SPC and BUS (Alarm Type) and the final 36 month alarm
status for SPC and BUS (True Alert Type).
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In order to evaluate the effect the denominator (sample size) has on the alerting
thresholds of each method, the sample size for the expected event rate of 50% was varied from
44 to 1787 for SPC and BUS (Figure 1). This shows that the denominator size plays a large role
in determining the number of alerts that should fire for any particular variation between the
expected and observed event rates. This is expected, as the size of the expected data improves
the confidence in that event rate value. An important trend to note is that for any given
denominator, the SPC method fires more frequently than the BUS method, but this difference is
reduced as the denominator sizes increase.
# Alerts
| BUS 44
0 SPC 44
61
Observed Rat
Figure 1: Illustration of Alert Firing for 50% Expected Event Rate of SPC and BUS from
Expected sample sizes of 44 to 1878.
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Discussion
There are a number of notable trends in the SPC and BUS alerting methodologies when
applied to this clinical data. First, both SPC and BUS are able to excellently discriminate a 'true'
alert in the first 24 months of data where the 36 th month is the gold standard. This suggests that
it is functioning within the statistical framework as an early detection system.
There is also a trend of decreasing performance as the expected event rate decreases.
This is most notable in the 50% expected event rate category. This degradation of performance
suggests that increasing event rates likely create greater variance in the monthly event rate which
could generate more alerts without the setting of a 'true alert' (cumulative month 36).
In addition, when each method is compared to the other, the SPC number of alerts shows
greater disagreement with the BUS 36th month alert than the BUS number of alerts and the SPC
36th month alert. Incorporation of prior month data into the BUS estimate creates a moving
baseline which accounts for the differences, but further exploration of this is necessary. Both
cross-analyses show generally lower AUC which is expected.
The primary limitation of this analysis is the LR modeling required to generate a
probability of outcome to allow observed event rate scaling. The ROC was relatively low,
although the calibration was adequate. This could impact the monthly event rate to be lower or
higher than observed, and could subsequently have an effect on the number of alerts fired for a
particular data set. As noted above, this is primarily due to the composite outcome (MACE) that
was chosen for the evaluation. The other limitation of this work is that there is no true gold
standard for whether or not a given data set should have been considered 'of concern.' This was
approximated by truncating the number of months in the analysis to 24 and setting the gold
standard to the result at 36 months, but this will generally inflate the ROC of each of the
methods.
Further work in this area will be done to evaluate the absolute and relative performance
between these methodologies for data with event rate trends. As noted above, the relative
performance between the methods was relatively similar with the noted exceptions. However,
greater variation between the methods might be observed for event rates with different event rate
trends (shown in Figure 2). These trends will be modeled and the methods will be evaluated,
such as: ascending event rates, descending event rates, "V" or descending then ascending event
48
Figure 2: Illustration of possible event rate trends in a data set, such as ascending, descending,
V, and inverse V event rate trends.
rates, and "Inverse V" or ascending then descending event rates. We suspect that each of the
methods will have strengths and weaknesses relating to the data event rate trends.
Overall, this sensitivity analysis shows that relative agreement between SPC and BUS
methods for low event rates (0.5% and 5%), and disagreement between the methods at high
event rates (50%). In addition, using the number of alerts by month appears to be a valid way to
determine when an outcome event rate is becoming a concern based on established baseline data.
Further work to establish a 'number of alerts' threshold for the purposes of sensitivity and
specificity will be required, and is underway.
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Thesis Summary
Risk prediction models have been widely used for prognostication and retrospective
comparisons. However, there are opportunities to adapt these methodologies to perform
prospective monitoring of clinical outcomes. Incorporation of these methods into automated
tools could help support the evolving field of medical post-marketing surveillance.
The performance of the most well-known mortality risk models for the outcome of death
in percutaneous coronary intervention were evaluated on Brigham & Women's Hospital clinical
data. All of the models retained good discrimination. While this was promising, all of the
models except the recent locally developed one showed poor calibration, suggesting that changes
over time as well as regional patient demographics and medical care delivered may play an
important role in the generalizability of a model. The preservation of discrimination supports the
use of these models for generic risk stratification, but poor calibration indicates that use of the
models for individual prognostication should be done with caution, and indicates the need for
further study.
An exploration of support vector machines as an alternative to logistic regression risk
modeling for individual prognostication was performed. While both modeling techniques had
excellent and relatively similar discrimination, the support vector machine models were
consistently superior in terms of calibration. This suggests that this method could provide
superior risk stratification and prognostication for use in the real-time safety monitoring
application.
A real-time safety monitoring system, DELTA, was designed with a SQL database for
back-end data storage and a web-based graphical user interface for user operation. The software
satisfied all pre-specified design requirements, which were 1) the ability to accept a generic flat
data table, 2) perform both retrospective and prospective analyses, 3) incorporate a
complimentary set of statistical methods for event rate monitoring, 4) provide user-configurable
alerting thresholds, and automated alert notification, and 5) support an unlimited number of
simultaneous datasets with nested analyses.
A pilot investigation evaluating the in-hospital mortality following implantation of drug-
eluting coronary artery stents was then performed with the system. The system performed as
expected, and event rates compared to University of Michigan bare-metal stent data were
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acceptably low using adapted statistical techniques including Statistical Process Control,
Bayesian Updating Statistics, and Logistic Regression.
Subsequently, sensitivity analyses between the SPC and BUS alerting methods were
performed to evaluate individual and relative performance of these measures on scaled event
rates for BWH in-hospital major adverse coronary events. A variety of baseline event rates were
evaluated. The analysis revealed relative agreement between SPC and BUS methods for low
event rates, but noted an increasing disagreement between the methods as observed event rates
escalated. In addition, the SPC method generated more alerts for a given analysis configuration
than BUS. Finally, using the number of alerts by month appeared to be a valid way to determine
a 'significant event rate.' Further work to establish specificity and sensitivity thresholds will be
required as gold standard data becomes available.
These research efforts have shown highlighted some of the limitations relating to
calibration in current risk modeling methods. Machine learning modeling methods may provide
improvements in this area. In addition, the design feasibility of a real-time automated
monitoring system was confirmed, some potentially useful statistical monitoring methodologies
were established and evaluated, and the utility and applicability of both logistic regression and
support vector machine modeling were explored for use in the application. Further work remains
to validate and scale up the application for use in multiple clinical environments.
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